Iterum Therapeutics announces publication of REASSURE trial in NEJM Evidence

Iterum Therapeutics (ITRM) reported that NEJM Evidence published results from its REASSURE Phase 3 clinical trial comparing oral sulopenem to oral Augmentin in adult women with uncomplicated urinary tract infections. “We are very pleased that NEJM Evidence have published the results from the REASSURE trial,” said Corey Fishman, Iterum’s Chief Executive Officer. “This article highlights the need for new antibiotics, like ORLYNVAH(TM), for the treatment of uUTI given the increasing rates of multidrug resistance to the currently available antibiotics. We expect ORLYNVAHTM to be available to treat women with hard-to-treat infections in the next quarter.”